• Users Online: 129
  • Print this page
  • Email this page
REVIEW ARTICLE
Year : 2018  |  Volume : 1  |  Issue : 1  |  Page : 26-37

Pneumonitis after precision oncology therapies: A concise review


Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Correspondence Address:
Dr. Ajay Sheshadri
Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Units 1462, Houston, Texas
USA
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/JIPO.JIPO_9_18

Get Permissions

With greater understanding of the molecular biology of cancer, precision oncology therapies are becoming increasingly prevalent. Adverse events associated with these therapies may cause significant harm to patients if not promptly recognized and treated. In this review, we focus on pneumonitis that occurs as a side effect of treatment with precision oncology agents. We discuss the incidence and time to onset of pneumonitis associated with a broad array of precision oncology agents. We highlight the common patterns of pneumonitis and offer a comprehensive approach to evaluation and treatment with therapy-specific guidelines where available.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed800    
    Printed35    
    Emailed0    
    PDF Downloaded115    
    Comments [Add]    

Recommend this journal